Docket #: S21-198
Use of Focal Adhesion Kinase Inhibitors To Reduce Scar Formation In Combination With Split Thickness Skin Grafts
Stanford inventors have discovered that applying a hydrogel containing an inhibitor of mechanotransduction pathways on top of a skin graft reduces scarring and promotes healing after repair of traumatic injuries like severe burn wounds.
Split thickness skin grafting (STSG) is the standard-of-care for repairing full thickness wounds, like severe burns. However, the repaired area after the graft exhibits fibrotic healing, which results in fragility, lack of flexibility, and scar contracture. Groups at Stanford and elsewhere have demonstrated that mechanotransduction pathways are involved in scarring and fibrosis and that Focal Adhesion Kinase (FAK) proteins are key signaling components in these pathways.
In this work, Stanford scientists test the principle that FAK inhibition is an effective strategy for reducing wound scarring and fibrosis using a previously validated and selective FAK inhibitor called VS-6062. They combine split thickness skin grafting with the application of collagen-pullulan hydrogels containing this FAK inhibitor and show in a porcine model that the addition of the inhibitor-containing hydrogel accelerates wound healing, reduces scarring, and blocks scar contracture as compared to hydrogels alone. The promising results of this straightforward method in a large animal model indicate a technology that is ripe for clinical trials and commercialization.
Applications
- Scar reduction, improved wound healing, and reduced wound contracture after skin graft repair of burn wounds or related soft-tissue defects
Advantages
- Improved function: Less wound contracture and greater flexibility of the skin around joints improves movement as compared to the standard-of-care skin graft alone
- Improved appearance: Less scarring than with grafting alone leads to improved aesthetic result for patients, increasing their quality of life
- IND-stage therapy: Promising results in porcine models and an Investigational New Drug (IND) application to the FDA in preparation indicate an advanced therapeutic product ready to move into patients soon
Publications
- In review
Patents
- Published Application: WO2023009439
- Published Application: 20240252494
Similar Technologies
-
The use of mechanotransduction inhibitors as a coating for surgical sutures to reduce scarring S23-082The use of mechanotransduction inhibitors as a coating for surgical sutures to reduce scarring
-
Use of Focal Adhesion Kinase Inhibitors To Improve the Quality and Appearance of Split Thickness Skin Grafts S20-006Use of Focal Adhesion Kinase Inhibitors To Improve the Quality and Appearance of Split Thickness Skin Grafts
-
Encapsulation and Local Delivery of Inhibitors of the Activator Protein 1 (AP-1) for Preventing Adhesions S23-384Encapsulation and Local Delivery of Inhibitors of the Activator Protein 1 (AP-1) for Preventing Adhesions